Literature DB >> 19401305

Blepharoptosis following oxaliplatin administration.

S Cecilia Lau1, Stephen I Shibata.   

Abstract

Oxaliplatin is a unique platinum derivative with anti-tumor activity in a number of malignancies, with neurotoxicity being a frequent side effect. Neurotoxicity can manifest in an acute phase and a chronic phase. The acute phase usually presents as dysesthesias of the hands and feet, jaw tightness, and pharyngolaryngo-dysesthesia, triggered and exacerbated by physical contact with cold temperatures. Although various other symptoms have been reported in the literature, little details are available. We report here, in detail, a case of blepharoptosis which appeared after repeated oxaliplatin infusions, and the disappearance of which seemed to be dependent on the infusion rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401305     DOI: 10.1177/1078155209104383

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  2 in total

1.  Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion.

Authors:  Elisabeth Krexner; Anika Stickler; Christian Prainer; Josef Finsterer
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

2.  Oxaliplatin-Associated Amaurosis Fugax.

Authors:  Kimitoshi Kubo; Noriko Kimura; Ryosuke Watanabe; Masayuki Higashino; Momoko Tsuda; Mototsugu Kato
Journal:  Case Rep Oncol       Date:  2021-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.